581 related articles for article (PubMed ID: 12649305)
1. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
2. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
[TBL] [Abstract][Full Text] [Related]
3. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig.
McLeod RL; Aslanian R; del Prado M; Duffy R; Egan RW; Kreutner W; McQuade R; Hey JA
J Pharmacol Exp Ther; 1998 Oct; 287(1):43-50. PubMed ID: 9765320
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
5. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
Ligneau X; Lin J; Vanni-Mercier G; Jouvet M; Muir JL; Ganellin CR; Stark H; Elz S; Schunack W; Schwartz J
J Pharmacol Exp Ther; 1998 Nov; 287(2):658-66. PubMed ID: 9808693
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of histamine H3 receptors in human saphenous vein and guinea pig ileum.
Valentine AF; Rizzo CA; Rivelli MA; Hey JA
Eur J Pharmacol; 1999 Jan; 366(1):73-8. PubMed ID: 10064154
[TBL] [Abstract][Full Text] [Related]
7. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography.
Mezzomo K; Cumming P; Minuzzi L
Eur J Pharmacol; 2007 Jun; 564(1-3):75-9. PubMed ID: 17350614
[TBL] [Abstract][Full Text] [Related]
9. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
[TBL] [Abstract][Full Text] [Related]
10. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
Sadek B; Elz S; Pertz HH; Stark H; Schunack W
Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
[TBL] [Abstract][Full Text] [Related]
11. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
13. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency.
Reidemeister S; Stark H; Ligneau X; Ganellin CR; Schwartz JC; Schunack W
Pharmazie; 2000 Feb; 55(2):83-6. PubMed ID: 10723763
[TBL] [Abstract][Full Text] [Related]
14. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
[TBL] [Abstract][Full Text] [Related]
15. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist.
Garbarg M; Arrang JM; Rouleau A; Ligneau X; Tuong MD; Schwartz JC; Ganellin CR
J Pharmacol Exp Ther; 1992 Oct; 263(1):304-10. PubMed ID: 1383495
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.
Leurs R; Tulp MT; Menge WM; Adolfs MJ; Zuiderveld OP; Timmerman H
Br J Pharmacol; 1995 Oct; 116(4):2315-21. PubMed ID: 8564266
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
[TBL] [Abstract][Full Text] [Related]
18. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons.
Dai H; Fu Q; Shen Y; Hu W; Zhang Z; Timmerman H; Leurs R; Chen Z
Eur J Pharmacol; 2007 Jun; 563(1-3):117-23. PubMed ID: 17350613
[TBL] [Abstract][Full Text] [Related]
19. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
[TBL] [Abstract][Full Text] [Related]
20. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]